Molecular factors involved in the hypolipidemic- and insulin-sensitizing effects of a ginger (Zingiber officinale Roscoe) extract in rats fed a high-fat diet

Appl Physiol Nutr Metab. 2017 Feb;42(2):209-215. doi: 10.1139/apnm-2016-0374. Epub 2016 Nov 2.

Abstract

Hypolipidemic and hypoglycemic properties of ginger in animal models have been reported. However, information related to the mechanisms and factors involved in the metabolic effects of ginger at a hepatic level are limited. The aim of the present study was to investigate molecular factors involved in the hypoglycemic and hypolipidemic effects of a hydroethanolic ginger extract (GE) in the liver of rats fed a high-fat diet (HFD). The study was conducted in male Wistar rats divided into the following 3 groups: (i) Rats fed a standard diet (3.5% fat), the control group; (ii) rats fed an HFD (33.5% fat); and (iii) rats fed an HFD treated with GE (250 mg·kg-1·day-1) for 5 weeks (HFD+GE). Plasma levels of glucose, insulin, lipid profile, leptin, and adiponectin were measured. Liver expression of glycerol phosphate acyltransferase (GPAT), cholesterol 7 alpha-hydroxylase, peroxisome proliferator-activated receptors (PPAR), PPARα and PPARγ, glucose transporter 2 (GLUT-2), liver X receptor, sterol regulatory element-binding protein (SREBP1c), connective tissue growth factor (CTGF), and collagen I was measured. Data were analyzed using a 1-way ANOVA, followed by a Newman-Keuls test if differences were noted. The study showed that GE improved lipid profile and attenuated the increase of plasma levels of glucose, insulin, and leptin in HFD rats. This effect was associated with a higher liver expression of PPARα, PPARγ, and GLUT-2 and an enhancement of plasma adiponectin levels. Furthermore, GE reduced liver expression of GPAT, SREBP1c, CTGF, and collagen I. The results suggest that GE might be considered as an alternative therapeutic strategy in the management of overweight and hepatic and metabolic-related alterations.

Keywords: dyslipidemia; dyslipidémie; gingembre; ginger; hepatic steatosis; insulin resistance; insulinorésistance; overweight; stéatose hépatique; surpoids.

MeSH terms

  • Adiponectin / blood
  • Animals
  • Catechols / analysis
  • Catechols / therapeutic use
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / prevention & control
  • Diet, High-Fat / adverse effects
  • Fatty Alcohols / analysis
  • Fatty Alcohols / therapeutic use
  • Glucose Transporter Type 2 / metabolism
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control*
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / therapeutic use*
  • Hypolipidemic Agents / chemistry
  • Hypolipidemic Agents / therapeutic use*
  • Insulin Resistance*
  • Liver / metabolism
  • Male
  • Overweight / blood
  • Overweight / diet therapy*
  • Overweight / metabolism
  • Overweight / physiopathology
  • PPAR alpha / metabolism
  • PPAR gamma / metabolism
  • Plant Extracts / chemistry
  • Plant Extracts / therapeutic use*
  • Plant Roots / chemistry
  • Rats, Wistar
  • Up-Regulation
  • Zingiber officinale / chemistry*

Substances

  • Adiponectin
  • Adipoq protein, rat
  • Catechols
  • Fatty Alcohols
  • Glucose Transporter Type 2
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • PPAR alpha
  • PPAR gamma
  • PPAR gamma, rat
  • Plant Extracts
  • Slc2a2 protein, rat
  • gingerol